CFO
CRL icon

Callan Family Office’s Charles River Laboratories CRL Stock Holding History

Callan Family Office’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$567K Buy
2,502
+67
+3% +$11.9K 0.01% 775
2026
Q1 		$420K Buy
2,435
+16
+0.7% +$2.97K 0.01% 826
2025
Q4 		$483K Buy
2,419
+395
+20% +$71.7K 0.01% 794
2025
Q3 		$317K Sell
2,024
-219
-10% -$34.8K 0.01% 692
2025
Q2 		$340K Buy
+2,243
New +$299K 0.01% 727

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Callan Family Office's CRL Position: Q2 2026 in Review

Callan Family Office increased its Charles River Laboratories (CRL) stake by 2.8% in Q2 2026, buying an estimated $11.9K and bringing the position to 2,502 shares worth $567K. The position accounts for 0.01% of the portfolio, ranked #775.

Callan Family Office first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Callan Family Office held 2,502 shares of Charles River Laboratories worth $567K as of Q2 2026.
  • Callan Family Office bought 67 Charles River Laboratories shares in Q2 2026, an estimated $11.9K.
  • Charles River Laboratories made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #775 holding.
  • Callan Family Office first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.